Can you tell us about emerging therapies for recurring ovarian cancer such as angiogenesis inhibitors and targeted biologic therapy?
Although we are talking about therapy in the setting of recurrent disease, the place in which the most impact has been made is not with recurring cancer but with the up front therapies. We’re good at getting people into the initial remission. We’re just not so good at keeping them there. We’re looking at approaches like immune therapies to use in that situation. Although we’re talking about recurrent disease, one of the goals of looking at and discovering new agents in the recurrent disease setting is to bring those treatments into the upfront treatment [initial treatment after diagnosis] where we cure patients. Let’s discuss angiogenesis inhibitors first. There are some patients who have tumors that just sit there. That’s fine, as long as they’re not causing any problems. Unfortunately, most tumors will actually go through a process where they invade. Usually that invasion requires going into a blood vessel. Those tumor cells then will move around and go to other sites and develop met
